ECG

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

Retrieved on: 
Friday, February 9, 2024

DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Limited (NASDAQ:PRE), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding (MOU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture. The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.

Key Points: 
  • The parties will also establish a Space Innovation Lab within the UAE Space Agency.
  • The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.
  • Concurrently, Danny Yeung, CEO of Prenetics will join the Board of Directors at Metavisionaries, fortifying its strategic vision.
  • I’m excited to contribute to Prenetics' mission and to translate space research into health innovations on Earth,” said Dr. James L. Green.

IRHYTHM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against iRhythm Technologies, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 8, 2024

Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • iRhythm develops and manufactures heart monitoring devices designed to diagnose arrythmias.
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

Sibel Announces its 4th FDA Clearance for Continuous Wearable Vital Signs Monitoring with ANNE® One and Additional Strategic Collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago

Retrieved on: 
Wednesday, February 7, 2024

CHICAGO, Feb. 7, 2024 /PRNewswire/ -- Sibel Health, a leading digital health company, announced today that its continuous wearable monitoring solution, ANNE® One, has received another 510(k) clearance from the U.S. Food and Drug Administration (FDA). The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements. In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.

Key Points: 
  • The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements.
  • In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.
  • Steve Xu MD, Co-Founder and CEO of Sibel Health, said "Our mission here at Sibel Health is to deliver Better Health Data for All®.
  • Sibel Health also announces a new collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago and its research enterprise, Stanley Manne Children's Research Institute.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Wednesday, February 7, 2024

The action is brought on behalf of all persons or entities that purchased or otherwise acquired iRhythm common stock between January 11, 2022, and May 30, 2023, inclusive (the “Class Period”).

Key Points: 
  • The action is brought on behalf of all persons or entities that purchased or otherwise acquired iRhythm common stock between January 11, 2022, and May 30, 2023, inclusive (the “Class Period”).
  • The complaint is based on an extensive investigation and a careful evaluation of the merits of this case.
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

EQS-News: TVM CAPITAL LIFE SCIENCE CO-LEADS $16 MILLION SERIES A FINANCING ROUND FOR VEKTOR MEDICAL TO REVOLUTIONIZE ARRHYTHMIA CARE

Retrieved on: 
Tuesday, February 6, 2024

Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.
  • The proceeds will be used to support the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool, which is transforming how electrophysiologists (EPs) approach ablation procedures.
  • Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.
  • Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach.

TVM Capital Life Science Co-Leads $16 Million Series A Financing Round for Vektor Medical to Revolutionize Arrhythmia Care

Retrieved on: 
Tuesday, February 6, 2024

MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.

Key Points: 
  • MUNICH, Germany and MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology.
  • Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.
  • Vektor’s vMap is the only FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, seamlessly leveraging only a 12-lead ECG.
  • Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach.

Vektor Medical Secures $16 Million Series A Funding

Retrieved on: 
Monday, February 5, 2024

Vektor Medical , a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science.

Key Points: 
  • Vektor Medical , a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science.
  • This funding underscores investor confidence in Vektor’s vision and ability to successfully execute its mission to revolutionize arrhythmia care.
  • “The medical community is being confronted with the necessity for change.
  • With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency,” said Rob Krummen, CEO of Vektor Medical.

HeartSciences Appoints New Scientific Advisory Board Member

Retrieved on: 
Thursday, February 1, 2024

Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.

Key Points: 
  • Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
  • “We are delighted to welcome Dr. Glicksberg, an elite data scientist and an instrumental leader in the establishment of the AI-ECG program at the Icahn School of Medicine at Mount Sinai, New York (Mount Sinai) to HeartSciences’ Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
  • As part of this process, we are actively expanding our Scientific Advisory Board to include industry experts and broaden our outreach.
  • I am impressed by their proven track record of innovation and look forward to contributing to HeartSciences at the forefront of this field.”

Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine’s SmartHeart® Technology, to Be Presented at ACC 24

Retrieved on: 
Thursday, February 1, 2024

The TELE-ACS trial is a pivotal study that marks a significant milestone in telemedicine and cardiovascular care.

Key Points: 
  • The TELE-ACS trial is a pivotal study that marks a significant milestone in telemedicine and cardiovascular care.
  • Erez Nachtomy, CEO of SHL Telemedicine, commented: “We would like to congratulate the team at Imperial College London on the acceptance of the TELE-ACS trial results for presentation at ACC 24.
  • This achievement is a testament to the researchers and their rigorous effort to conduct this groundbreaking work.
  • We very much look forward to seeing the presentation at ACC 24 which will share the embargoed full trial results with the global cardiology community.”
    ACC 24 Participants are invited to add the session to their itinerary using the following link: https://www.abstractsonline.com/pp8/#!/10973/presentation/22832

Smart Medical Devices Market Forecast: Substantial Growth to Reach US$271.3 Billion by 2028

Retrieved on: 
Tuesday, January 30, 2024

The global smart medical devices market is estimated to grow at a CAGR of 10.33% reaching US$271.343 billion in 2028 from US$136.395 billion in 2021.

Key Points: 
  • The global smart medical devices market is estimated to grow at a CAGR of 10.33% reaching US$271.343 billion in 2028 from US$136.395 billion in 2021.
  • The global smart medical devices market growth is being propelled by the increasing demand for wireless and smartphone-compatible medical equipment, device technology breakthroughs, and increased consumer awareness of fitness.
  • The rise in the prevalence of chronic diseases including diabetes, cardiovascular, and respiratory problems has a big impact on the global smart medical devices market.
  • Indian government initiatives are also playing a significant role in the growth and development of the smart medical devices market in the country.